News | Optical Coherence Tomography (OCT) | May 16, 2016

OCT Helps Predict Significant Side Branch Ostium Stenosis

Optical Coherence Tomography Bifurcation Study (ORBID) identified predictors in SCAI late-breaker

OCT, ORBID study

May 16, 2016 — In a new study using optical coherence tomography (OCT), an invasive laser imaging technique that provides high-resolution images, researchers found that maximum lipid arc and the presence of lipid plaque contralateral to the side branch (SB) ostium before stenting may contribute to significant side branch ostium stenosis (SBOS) after stenting. The results of the ORBID study were presented as a late-breaking clinical trial at the 2016 Society for Cardiovascular Angiography and Interventions (SCAI) annual meeting.

Stenting in the main vessel can result in significant SBOS, making it important for interventional cardiologists to be able to identify at-risk patients before they undergo percutaneous coronary intervention (PCI). Significant SBOS is defined as a blockage of 50 percent or more based on angiography. ORBID study researchers aimed to identify predictors of significant SBOS before a stent is introduced in the main vessel, using OCT, which is in the research-phase for this application. OCT is more accurate and provides higher resolution imaging than ultrasound, which is currently the most widely used method in clinical care.

“When inserting a stent into the main vessel of a patient, we have the option of also inserting a wire in the side branch in case SBOS occurs,” said Samin Sharma, M.D., FSCAI, an investigator of the study and director of clinical cardiology and intervention, dean of international clinical affiliations, and president of the Mount Sinai Heart Network, The Mount Sinai Hospital, N.Y. “In our study, OCT proved helpful in identifying predictors of SBOS prior to PCI, which may allow for avoiding inserting a wire in the side branch in select cases.”

The prospective single-center study analyzed 30 patients who did not have initial blockage in the SB ostium. Post-stenting significant SBOS was observed in 30 percent of patients. Affected patients were characterized by a higher prevalence of lipids in the blood (100 vs. 64 percent, p = 0.040) and spotty calcifications (60 vs. 0 percent, p = 0.005).

A multivariate logistic regression analysis identified maximal lipid arc (odds ratio [OR]: 1.014, p = 0.038) and the presence of lipid plaque contralateral to SB ostium (OR: 8.14, p = 0.046) before stenting as independent predictors of significant SBOS.
“This initial study indicates that OCT is a helpful tool in identifying predictors of significant SBOS in patients before they receive a stent,” Sharma said. “In the future, this imaging technology could be broadly introduced as a tool to identify at-risk patients, thereby giving interventional cardiologists more information before doing bifurcation stenting.”

Sharma reported no disclosures. The study was sponsored by Boston Scientific.

For more information: www. 


Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init